Illumina said in a recent filing with the US Securities and Exchange Commission that Paul Grint plans to retire from the firm's board of directors, effective as of the next Illumina stockholder meeting.

Grint has been a director since 2005. He's currently senior vice president at Forest Research Institute, and was previously the chief medical officer at Kalypsys. He has also served as an executive at Zephyr Sciences, Pfizer, IDEC Pharmaceuticals, and Schering-Plough.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.